Interactions on record — worth a quick check against your medications. Based on 3 of 5 ingredients. Check your meds →
Dietary supplement

Total Probiotic Ingredients & Drug Interactions

by BIOHM

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Total Probiotic is a dietary supplement by BIOHM with 5 active ingredients. Its ingredients are commonly taken for digestive health and balance, diarrhea (including antibiotic-related), vaginal yeast and bacterial infections.Based on those ingredients, 222 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are L. acidophilus 16 axg, B. breve 19 bx, S. boulardii 16 mxg. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Total Probiotic by BIOHM

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 5 active ingredients.
  • “BIOHM FX Probiotic Blend” is a proprietary blend — the label gives one combined amount (630 mg) without saying how much of each component you get.

BIOHM Total Probiotic is a 5-ingredient capsule built around live beneficial bacteria and yeast. The active ingredients are L. acidophilus, L. rhamnosus, S. boulardii (a beneficial yeast), B. breve, and amylase (an enzyme).

These are meant to support digestive health. The capsule itself contains cellulose and hypromellose as inactive ingredients.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: break down digestive plaque and address gut balance.
  • We looked for evidence on: Antibiotic-associated diarrhea, Colic, Constipation, Clostridioides difficile infection, Crohn disease, Inflammatory bowel disease (IBD) — and 4 related terms.
  • The strongest evidence on file: Saccharomyces Boulardii is rated "Possibly Effective" for Antibiotic-associated diarrhea (Natural Medicines).
  • Also on file: Saccharomyces Boulardii is rated "Possibly Effective" for Rotaviral diarrhea, Clostridioides difficile infection.
  • Also on file: Lactobacillus Acidophilus is rated "Possibly Effective" for Antibiotic-associated diarrhea, Irritable bowel syndrome (IBS).

The evidence for these ingredients is mixed. L. acidophilus is possibly effective for irritable bowel syndrome, Helicobacter pylori infection, antibiotic-associated diarrhea, and bacterial vaginosis, but there isn't enough reliable data yet on its use for acute respiratory distress syndrome.

S. boulardii is possibly effective for rotaviral diarrhea, travelers' diarrhea, antibiotic-associated diarrhea, necrotizing enterocolitis, Clostridioides difficile infection, and Helicobacter pylori. B. breve shows insufficient evidence for allergic rhinitis and antibiotic-associated diarrhea, and appears possibly ineffective for age-related cognitive decline and sepsis.

We don't have effectiveness data on file for L. rhamnosus or amylase.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

L. acidophilus is generally well tolerated in healthy adults and children, though rare cases of serious infection (such as bacteremia or endocarditis) have been reported — most likely in people whose bacteria translocated from elsewhere in the body. Mild GI side effects like bloating, flatulence, and abdominal discomfort can occur but are uncommon.

S. boulardii is generally safe for healthy adults but should be avoided if you're critically ill or immunocompromised; very rarely it has caused fungemia, especially in ICU patients with central lines. Mild GI complaints like nausea and flatulence are rare.

B. breve is generally well tolerated in healthy people but caution is advised if you're severely ill or immunocompromised; rare cases of bacteremia have occurred in preterm infants and critically ill patients. Bloating and flatulence are possible.

All three live-organism ingredients carry a small risk of serious infection in vulnerable populations — talk with your doctor before use, especially if you're critically ill, have a central line, or a weakened immune system.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Saccharomyces Boulardii, Lactobacillus Acidophilus, Bifidobacterium Breve.
  • The most serious interaction on file is rated Moderate.
  • For scale: 222 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check your medications if you take antibiotic drugs — L. acidophilus and B. breve may lose effectiveness if dosed together; separate them by a few hours. If you use antifungal drugs, the same timing issue applies to S. boulardii (Minor severity).

Ask your pharmacist or doctor how to space them out.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This probiotic may help with diarrhea, IBS, or certain infections, but the evidence varies by ingredient. If you take antibiotics or antifungals, timing matters — don't take them at the same time as this product.

If you're very ill, immunocompromised, or hospitalized, check with your doctor first; probiotics aren't for everyone in those situations. Run your exact medications through the checker below before you start.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 5 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jul 18, 2023.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Total Probiotic, straight from the product label.

Brand BIOHM
Barcode (UPC) 85548607438
Net contents 30 Veggie Capsule(s)
Market status On market
Date entered into DSLD Jul 18, 2023
DSLD ID 291960
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegetarian, Adult (18 - 50 Years), Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Total Probiotic by BIOHM, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
30
UPC/BARCODE
85548607438
IngredientAmount% DV
Amylase0 NP--
BIOHM FX Probiotic Blend630 mg--
L. rhamnosus 18 fx0 NP--
L. acidophilus 16 axg0 NP--
S. boulardii 16 mxg0 NP--
B. breve 19 bx0 NP--

Other ingredients: Cellulose, Hypromellose

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Innovation + science + quality The first scientifically researched probiotic that combines good bacteria and good fungi with a powerful enzyme.

Good bacteria + good fungi

BIOHM FX 30 billion CFUs

Formulation

Total Probiotic works to break down digestive plaque and address total gut balance.

Non-GMO Dairy-free Soy-free Gluten-free

Vegetarian

Supports total gut balance Breaks down digestive plaque Clinically tested + shelf stable

Suggested/Recommended/Usage/Directions

Directions for use Take one (1) capsule daily with food. Can use alone or with BIOHM Prebiotic Boost. Capsule can be opened and mixed into your favorite food or drink.

Precautions

Warnings Consult your healthcare provider if pregnant or nursing, taking medication, or have a medical condition.

Keep out of reach of children.

Do not use if any part of this package is torn, open, or damaged.

Storage

Store at room temperature. No refrigeration necessary.

Brand IP Statement(s)

BIOHM FX 30 billion CFUs

FDA Statement of Identity

Dietary Supplement

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

See for yourself

Total Probiotic by BIOHM label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Total Probiotic by BIOHM

These are the 5 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

BIOHM FX Probiotic Blend

630 mg per serving

Other (inactive) ingredients: Cellulose, Hypromellose. These complete the product’s ingredient list but are not active constituents.

Interaction report

Total Probiotic by BIOHM Drug Interactions

Want to check YOUR meds against Total Probiotic?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
222Drugs
182 Moderate 40 Minor

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Total Probiotic with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

L. acidophilus 16 axg1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus acidophilus with antibiotic drugs might decrease the effectiveness of L. acidophilus.
L. acidophilus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. acidophilus preparations by at least two hours.

Likelihood Probable Evidence D

B. breve 19 bx1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium breve with antibiotic drugs might decrease the effectiveness of B. breve.
Since B. breve preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. breve preparations by at least 2 hours.

Likelihood Probable Evidence D

S. boulardii 16 mxg1 drug type · 40 drugs

Antifungals

Theoretically, taking antifungals with Saccharomyces boulardii might decrease the effectiveness of Saccharomyces boulardii.
S. boulardii is a live yeast. Therefore, simultaneously taking antifungals might kill a significant number of the organisms.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Total Probiotic, from the product label.

BIOHM

See all BIOHM products
Name
BIOHM Health LLC
Street Address
425 Literary Road, Suite 100
City
Cleveland
State
OH
ZipCode
44113
Web Address
BIOHMHEALTH.COM
Pharmacist Counseling Corner

Total Probiotic by BIOHM: Common Questions

Does Total Probiotic by BIOHM interact with any medications?
Yes. Based on its ingredients, Total Probiotic has a known interaction with 222 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Total Probiotic contains 5 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Does this probiotic work for diarrhea?
S. boulardii in this product is possibly effective for rotaviral diarrhea, travelers' diarrhea, antibiotic-associated diarrhea, and Clostridioides difficile infection. L. acidophilus is possibly effective for antibiotic-associated diarrhea. So yes, there's decent evidence for certain types, but it depends which kind of diarrhea you have — talk to your doctor about whether this is right for your situation.
What's in the capsule besides the probiotics?
Besides the live bacteria and yeast, each capsule contains cellulose and hypromellose — these are inactive ingredients that help hold the capsule together. There are no added fillers beyond these.
Can I take this with my antibiotics?
Not at the same time. The antibiotic will kill the live L. acidophilus and B. breve in this product. Space them out by a few hours — ask your pharmacist for the best timing for your specific antibiotic.
Is this safe if I have a weak immune system?
You should talk with your doctor first. S. boulardii especially should be avoided if you're critically ill or immunocompromised; rare cases of serious yeast infection have been reported in those groups. The other ingredients carry small risks too in vulnerable populations, so medical guidance is important.
Can I take this during pregnancy?
We don't have pregnancy safety data on file for the ingredients in this product, so we can't say one way or the other. Talk with your doctor or pharmacist about whether it's right for you during pregnancy — that's a personal decision based on your full medical picture.
What are these different strains of bacteria for?
Each strain has different roles in the gut. L. acidophilus and B. breve are bacteria; S. boulardii is a beneficial yeast. Together they're meant to support digestive health and help with conditions like IBS, diarrhea, and infection-related digestive problems. The evidence is stronger for some uses than others.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Total Probiotic is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Total Probiotic label
Sources

Sources & How We Checked

Total Probiotic's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 50 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Lactobacillus Acidophilus 15 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48(10):1127-35 PubMed
  3. Chatterjee S, Kar P, Das T, Ray S, Gangulyt S, Rajendiran C, Mitra M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated
  4. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M,Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-c
  5. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  6. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  7. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabete
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Xiao SD, Zhang DZ, Lu H, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20(5):253-60.
  10. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  11. Ozer M, Goksu SY, Shahverdiani A, Mustafa M. Lactobacillus acidophilus-induced endocarditis and associated splenic abscess. Case Rep Infect Dis 2020;2020:1382709.
  12. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis 2020;52(5):534-540. PubMed
  13. Stoffer JN, Slingsby TJ, Giuliari GP. Lactobacillus acidophilus endophthalmitis after intravitreal bevacizumab injection requiring intraocular lens explantation. Can J Ophthalmol 2022;57(1):e21-e22. PubMed
  14. Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 2006;73(2-3):107-10.
  15. Hui J, Ren Y, Wang Y, Han Q. Lactobacillus acidophilus endophthalmitis postcataract operation: A case report with a literature review. Ocul Immunol Inflamm 2023.

See these in context on the Lactobacillus Acidophilus monograph →

Saccharomyces Boulardii 26 references
  1. Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999;28:930.
  2. Pletinex M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5. DOI
  3. Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving ultra-levure therapy. Clin Infect Dis 1998;27:222-3.
  4. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999;13:1663-8.
  5. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22. PubMed
  6. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000;8:504-5. PubMed
  7. Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001;39:551-9.
  8. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993;31:129-34.
  9. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-80. PubMed
  10. Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004;38:S67-9. PubMed
  11. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34. PubMed
  12. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., and Malbrunot, C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28(6):797-801. PubMed
  13. Riquelme, A. J., Calvo, M. A., Guzman, A. M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., and Labarca, J. A. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin.Gastroenterol. 2003;36(1):41- PubMed
  14. Cherifi, S., Robberecht, J., and Miendje, Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004;59(4):223-224. PubMed
  15. Ellouze O, Berthoud V, Mervant M, Parthiot JP, Girard C. Septic shock due to Sacccaromyces boulardii. Med Mal Infect. 2016;46(2):104-105.
  16. Appel-da-Silva MC, Narvaez GA, Perez LRR, Drehmer L, Lewgoy J. Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. Med Mycol Case Rep. 2017;18:15-7. PubMed
  17. Atici S, Soysal A, Karadeniz Cerit K, et al. Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Med Mycol Case Rep. 2017;15:33-35. PubMed
  18. Martin IW, Tonner R, Trivedi J, et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis. 2017;87(3):286-8. PubMed
  19. Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr 2017;35(3):361-4.
  20. Roy U, Jessani LG, Rudramurthy SM, et al. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses 2017;60(6):375-380.
  21. Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr. 2017 Jul-Sep;35(3):361-364. doi: 10.1590/1984-0462/;2017;35;3;00014.
  22. Flatley EA, Wilde AM, Nailor MD. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis. 2015;24(1):21-4. PubMed
  23. Ventoulis I, Sarmourli T, Amoiridou P, et al. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. J Fungi (Basel). 2020;6(3):98. PubMed
  24. Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 2021;64(12):1521-1526.
  25. Rannikko J, Holmberg V, Karppelin M, et al. Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. Emerg Infect Dis 2021;27(8):2090-6.
  26. Awoyemi A, Mayerhofer C, Felix AS, et al. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine 2021;70:103511. PubMed

See these in context on the Saccharomyces Boulardii monograph →

Bifidobacterium Breve 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  4. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-81. PubMed
  5. Sakurai Y, Watanabe T, Miura Y, et al. Clinical and bacteriologic characteristics of six cases of Bifidobacterium breve bacteremia due to probiotic administration in the neonatal intensive care unit. Pediatr Infect Dis J 2022;41(1):62-65. PubMed
  6. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  7. Wakabayashi Y, Nakayama S, Yamamoto A, et al. First case of necrotizing fasciitis and bacteremia caused by Bifidobacteriumbreve. Anaerobe 2022;76:102613.
  8. Takeda Y, Ota K, Kondo A, et al. A case of necrotizing fasciitis caused by Bifidobacterium breve. IDCases 2022;31:e01667. PubMed
  9. Suwantarat N, Romagnoli M, Wakefield T, Carroll KC. Ventriculoperitoneal shunt infection caused by Bifidobacterium breve. Anaerobe 2014;28:1-3. PubMed

See these in context on the Bifidobacterium Breve monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring